- Post-Effective Amendment to an S-8 filing (S-8 POS)
12 Marzo 2009 - 4:03AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on March 11, 2009
Registration
No. 333-39429
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES
ACT
OF 1933
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
13-3304550
|
|
(State
or other jurisdiction
|
(IRS
Employer
|
|
of
incorporation or organization)
|
Identification
Number)
|
|
221
West Grand Avenue
Montvale,
New Jersey
(Address
of Principal Executive Offices)
|
07645
(Zip
Code)
|
|
|
|
|
ALTEON
INC. AMENDED 1995 STOCK OPTION PLAN
|
|
(Full
title of the plan)
|
|
Noah
Berkowitz, M.D., Ph.D.
President
and Chief Executive Officer
|
Copies
to:
Megan
N. Gates, Esq.
|
|
Synvista
Therapeutics, Inc.
|
Mintz,
Levin, Ferris, Glovsky & Popeo, P.C.
|
|
221
West Grand Avenue
|
One
Financial Center
|
|
Montvale,
NJ 07645
|
Boston,
MA 02111
|
|
(201)
934-5000
|
(617)
542-6000
|
|
(Name,
address, including zip code, and telephone
number,
including area code, of agent for service)
|
|
DEREGISTRATION
OF UNSOLD SECURITIES
On
November 4, 1997, Synvista Therapeutics, Inc., formerly known as Alteon Inc.
(the “Company”), filed a registration statement on Form S-8 (File No. 333-39429)
(the “Registration Statement”). The Registration Statement registered
a total of 1,000,000 shares of the Company’s common stock, par value $0.01 per
share (the “Common Stock”), to be issued pursuant to the Company’s Amended 1995
Stock Option Plan. This offering has been terminated because the
Company intends to deregister its Common Stock under the Securities Exchange Act
of 1934, as amended. Consequently, in accordance with an undertaking
made by the Company in the Registration Statement to remove from registration,
by means of a post-effective amendment, any of the securities that remain unsold
at the termination of the offering, the Company hereby removes from registration
the securities of the Company that are registered but unsold under the
Registration Statement.
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds
to believe that it meets all the requirements for filing on Form S-8 and has
duly caused this Post-Effective Amendment No. 1 to its Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Montvale, State of New Jersey on March 11, 2009.
|
|
SYNVISTA
THERAPEUTICS, INC.
|
|
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
President
and Chief Executive Officer
|
Pursuant to the requirements of the
Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the
dates indicated.
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
President,
Chief Executive
|
|
March
11, 2009
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
Officer
and Director
|
|
|
|
|
|
|
|
|
|
/s/ Wendy A. Milici
|
|
Principal
Financial Officer and
|
|
March
11, 2009
|
|
Wendy
A. Milici
|
|
Principal
Accounting Officer
|
|
|
|
|
|
|
|
|
|
/s/ John F. Bedard
|
|
Director
|
|
March
11, 2009
|
|
John
F. Bedard
|
|
|
|
|
|
|
|
|
|
|
|
/s/ William Federici
|
|
Director
|
|
March
11, 2009
|
|
William
Federici
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Mary C. Tanner
|
|
Director
|
|
March
11, 2009
|
|
Mary
C. Tanner
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Wayne P. Yetter
|
|
Director
|
|
March
11, 2009
|
|
Wayne
P. Yetter
|
|
|
|
|
S.Y. Bancorp (AMEX:SYI)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
S.Y. Bancorp (AMEX:SYI)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
